Trade Regulus Therapeutics Inc. - RGLS CFD

Regulus Therapeutics Inc. Company profile

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Regulus Therapeutics Inc revenues decreased from $10M to $0K. Net loss increased 77% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects research increase of 16% to $16.5M (expense), general increase of 15% to $7.9M (expense), Stock-based Compensation in SGA increase of 9% to $2.1M (expense).

Equity composition

Common stock $.001 Par, 10/12, 200M auth., 34,130,393 issd. Insider Owns 67.04%.